CD7 and acute lymphoblastic leukemia: The pan T cell marker CD7 was chosen as the target for the antibody–toxin conjugate used here, since CD7+ T cells and B cells are associated with a multitude of diseases, such as most cases of T-ALL [29], some cases of AML [30], and B-ALL [31,114], as well as GvHD [32,33].